Tags : NIAID

Clinical Trials COVID-19

Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to

Shots:  The independent DSMB recommended pausing the enrollment of the ACTIV-3 clinical trial. The trial is evaluating Lilly’s bamlanivimab (LY-CoV555, 7000mg) + remdesivir as a treatment for COVID-19 in hospitalized patients, and is sponsored by the NIAID Lilly trusts the judgment & supports independent DSMB decisions to exercise caution in ensuring the safety of the […]Read More

Weekly Snapshot

Weekly Snapshot (Jul 06 – 10, 2020)

1. LEO Reports the US FDA’s Acceptance of BLA for Tralokinumab to Treat Adults with Moderate to Severe Atopic Dermatitis Published Date: Jul 10, 2020 | Tags: LEO, Reports, US, FDA, Acceptance, BLA, Tralokinumab, Treat, Adults, Moderate to Severe, Atopic Dermatitis 2. Philips Collaborates with BioIntelliSense to Enhance Remote Patient Monitoring Published Date:  Jul 10, […]Read More

COVID-19 Pharma

RedHill Biopharma Collaborates with NIAID to Investigate RHB-107 (upamostat, WX-671)

Shots: RedHill in collaboration with NIAID will evaluate RHB-107 in non-clinical studies to determine its activity against SARS-CoV-2. The agreement will facilitate the pre-clinical evaluation of RHB-107 as a treatment for COVID-19 Additionally, RedHill is evaluating opaganib (Yeliva, ABC294640) against COVID-19. On Apr 17, the company unveils about the compassionate use of Opaganib is underway […]Read More